


## NCTN Endocrine/Neuroendocrine Cancer Trials Portfolio (Open as of 4/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## NCTN Endocrine/Neuroendocrine Cancer Trials (Open as of 4/15/2026)

| Protocol Number | Phase  | Protocol Title  |
|-----------------|--------|---|
| <b>A021901</b>  | II     | Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors   |
| <b>A092204</b>  | II     | A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer          |
| <b>CCTG-NE1</b> | II     | NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET   |
| <b>S2012</b>    | II/III | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) |
| <b>S2104</b>    | II     | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors  |